Cargando…
BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer
Concurrent/adjuvant cisplatin-based chemoradiotherapy is regarded as the standard of treatment for locoregionally advanced nasopharyngeal carcinoma (NPC). However, patients who do not respond to cisplatin suffer, rather than benefit, from chemotherapy treatment. The goal of this study was to identif...
Autores principales: | Kuang, Chun-mei, Fu, Xiang, Hua, Yi-jun, Shuai, Wen-di, Ye, Zhi-hua, Li, Yingchang, Peng, Qi-hua, Li, Yi-zhuo, Chen, Shuai, Qian, Chao-nan, Huang, Wenlin, Liu, Ran-yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520926/ https://www.ncbi.nlm.nih.gov/pubmed/28617432 http://dx.doi.org/10.1038/cddis.2017.271 |
Ejemplares similares
-
High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy
por: Fu, Xiang, et al.
Publicado: (2015) -
Transducin β-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in Nasopharyngeal Carcinoma via activation of NF-κB pathway
por: Chen, Shu-Peng, et al.
Publicado: (2014) -
SIRT6 overexpression induces apoptosis of nasopharyngeal carcinoma by inhibiting NF-κB signaling
por: Ouyang, Lei, et al.
Publicado: (2018) -
Viral Restriction Activity of Feline BST2 Is Independent of Its N-Glycosylation and Induction of NF-κB Activation
por: Wang, Weiran, et al.
Publicado: (2015) -
Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)